Service areas: Western NY, Western PA, Northern PA
Volume: 196,694 outpatient visits; 4,928 inpatient admissions; 30,758 patients under active care; 133 beds
Clinical Research: 1,218 intervention accruals; 40,798 non-intervention accruals
Learn more about clinical trials at Roswell Park Cancer Institute.
Roswell Park Cancer Institute (RPCI), located in downtown Buffalo, NY, was founded in 1898 by Dr. Roswell Park, one of the nation's most pre-eminent surgeons and arguably the first to articulate the importance of translational research in a cancer center. His revolutionary model of a "multidisciplinary approach" to cancer – with scientists and clinicians working in concert and in consult – has become the standard by which all modern-day comprehensive cancer centers are measured.
RPCI is the only National Cancer Institute-designated comprehensive cancer center in Upstate New York. It was among the first to achieve this status in 1974 and has held that distinction, without interruption, to the present. This designation means that a cancer center's combined research, treatment, prevention, and educational programs have weathered extensive peer review, met rigorous national standards, and made fundamental contributions to reducing the cancer burden. RPCI is credited with initiating the world's first chemotherapy studies and pioneering the prostate-specific antigen (PSA) test. The Institute is also a charter member of the prestigious National Comprehensive Cancer Network, an alliance of the nation's leading cancer centers, and has been designated a Magnet Center for nursing excellence by the American Nurses Credentialing Center.
As one of only a handful of free-standing comprehensive cancer centers, RPCI has emerged as a national and international leader in the cancer arena, forging an exemplary reputation based on the combined strength of its basic/translational research, multidisciplinary oncology teams, educational programs and compassionate staff. A seamless interface of scientific inquiry and clinical application, and an aggressive clinical research studies program, afford patients access to promising breakthroughs in cancer diagnostics, technologies and therapies. Learn more about clinical trials at Roswell Park Cancer Institute.
Over the last decade, RPCI has undergone major growth, initiating one of the nation's first centers dedicated to phase I cancer clinical trials, and setting itself apart as a leader in surgical robotics, vitamin D research,
IL-2 therapy, studies targeting tumor microenvironment and behavior/prevention, and the development and testing of new agents and technology. Committing the infrastructure, intellectual capital, and necessary resources to convert its scientific discoveries into real-world products/applications, RPCI has established several biotech spin-off companies, and formed strategic partnerships with investigators and centers throughout the world. Despite a national nursing shortage, RPCI has sustained a "zero vacancy, waiting list only" Nursing Department over the last several years.